Overall, these findings indicated that B7H3/EGFR co-expression was highly prevalent in advanced NSCLC and correlated with poor survival and potentially impaired anti-tumor immunity, thereby underscoring the significance and promising clinical application of effective anti-EGFR/anti-B7H3 bsAbs. This evidence concerns the gene CD276 and neoplasm.